×

Stocks Merck & Co Inc

  • With a slew of banks set to report earnings this week, the Fast Money desk is closely watching the action in the financials. Is weakness already priced in?

  • Stocks rallied Tuesday, led by health-care stocks as a key Senate-seat vote in Massachusetts today could change the course of health-care reform. Citigroup bounced back after an initial dip on disappointing results.

  • Were you so preoccupied with tech on Thursday that you missed the important action in Pharma. If so, Pete Najarian has got you covered!

  • The Dow Jones Industrial Average is currently trading near 10,700, but Jeff Hirsch, editor at Stock Traders Almanac told investors that the index could reach 15,000 by 2011. He shared his insights.

  • Winterizing Your Portfolio - A CNBC Special Report

    Wall Street staged another late-day rally as investors were undeterred by a weak picture in the jobs market and retail, as well as a government move to punish bailed-out bankers.

  • Winterizing Your Portfolio - A CNBC Special Report

    Wall Street's stumble over weak economic trends was a short one, as investors turned an early loss into a modest gain despite disappointments in jobs and retail sales.

  • Find out what top analysts are saying about Mastercard, Merck and more. How should you be positioned, now?

  • Stocks closed higher, pushing the Dow average to a fresh 15-month closing high, as investors bought financial, technology and pharmaceutical shares.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks closed higher as a holiday rally got a further push from big technology, banks and commodities, though most investors took Christmas Eve off.

  • Stocks pushed higher on Tuesday, as investors weighed a big jump in home sales against weaker-than-expected economic growth. Will the gains continue into the new year? Jeffrey Kleintop, chief market strategist at LPL Financial, and Bill Smead, CEO and CIO of Smead Capital Management, weighed in.

  • 2009's Dogs of the Dow—the top 10 Dow stocks whose dividend is the highest fraction of their price—failed to beat the market this year. So will the same be true in 2010? Paul Hickey, co-founder of Bespoke Investment Group, shared his view.

  • Growth in 2010 will be stronger than what the markets expect, said Barry Knapp, head of U.S. portfolio strategy at Barclays. He shared his stock picks and market outlook for next year.

  • Eli Lilly did the expected today, but investors were hoping for more. Bears mauled the drug maker, unloading shares and snapping up puts, after management failed to address concerns about major patent expirations beginning in 2011.

  • Senate Democrats came to an agreement on Tuesday to replace the controversial government-run public insurance option with a scaled-back non-profit plan. So which companies in the health care sector are worth investing in? John Sullivan, director of research and health care investment strategist at Leerink Swann, shared his insight.

  • Following months of negotiations, General Electric and Comcast announced today a definite agreement to form a joint venture.  Here is a look at the top 10 M&A transactions this year.

  • With the health care debate continuing, how can investors make money in the sector? Barbara Ryan, managing director and senior pharmaceuticals analyst at Deutsche Bank Securities, and Charles Boorady, health care providers analyst at Citigroup, shared their insights.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks finished lower Friday, despite a last-ditch attempt to rally, as technology shares took yet another hit — this time it was weak earnings from PC maker Dell. Still , for the week, the Dow gained about 50 points.

  • The S&P 500 fell for a third straight day on Friday after weaker than-expected results from Dell and DR Horton left investors questioning the strength of the recovery.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks declined Friday as technology shares took yet another hit — this time it was weak earnings from PC maker Dell. Merck was among the few gainers today as investors moved into classically safe bets like health care, consumer staples and utilities.

  • Earlier this week I reported that Dr. Allen Taylor who ran the Abbott vs. Merck cholesterol drug study, which Abbott's drug Niaspan won, would only say that ABT has paid him more than $10,000 in lecture and consulting fees. But he wouldn't be any more specific than that.